National and Kapodistrian University of Athens
Μελέτη βιολογικών δεικτών σε ασθενείς με πλασματοκυτταρικές δυσκρασίες και νεφρική συμμετοχή
Abstract
dc:descriptionMonoclonal Gammopathy of Renal Significance (MGRS) includes a wide range of pathologic entities associated with a low-grade plasma cells or B-cells clone, which produce monoclonal immunoglobulin that is associated by a direct or indirect mechanism with renal damage. AL amyloidosis with renal involvement is the most common MGRS. Patients with MGRS are at increased risk of developing end-stage renal disease. In AL amyloidosis, staging systems and response to therapy for renal disease are based on proteinuria and eGFR estimated with the use of serum creatinine. However, these biomarkers are affected when the damage in the kidney is already advanced. For the remaining MGRS, data on staging and treatment are scarce due to their rarity. The main objective of this thesis was to study the role of novel biomarkers in patients with MGRS. To this end, we measured CysC, suPAR and vWF in the serum of patients with AL amyloidosis. Furthermore, we used CysC to estimate eGFR based on the available equations and compared their performance with eGFR using creatinine. Regarding the role of CysC we showed that it is a strong and independent predictor of renal outcome. At diagnosis, CysC levels > 1.9 mg/L were strongly associated with higher risk of initiating dialysis and in combination with the established renal staging system could distinguish a subgroup of patients with extremely unfavorable renal outcome. At 6 months from the start of treatment, CysC increase by 1 mg/L was a very strong predictor of the risk of progression to end-stage renal disease, regardless of the level of renal response based on the established criteria. Regarding the data on suPAR we found that it also had prognostic value for the outcome of renal disease, at diagnosis and during treatment. Baseline suPAR values > 6.6 ng/L were associated with a higher probability of eGFR decline and with renal progression at 6 months. At 6 months, both the absolute levels of suPAR and the percentage change were strongly associated with the likelihood of initiating dialysis, regardless of renal response. Because renal damage can also be associated to endothelial dysfunction, we also studied vWF:Ag. We found that elevated vWF:Ag levels were associated with a significantly higher probability of initiating dialysis. Then, we studied the clinical characteristics and the outcome of patients with AL amyloidosis and end-stage renal disease undergoing dialysis. We found that survival after dialysis initiation remains poor (28 months). Factors associated with inferior survival were cardiac involvement, lambda light chain type, increased bone marrow infiltration, and dFLC ≥ 50mg/L at the time of dialysis initiation. Having achieved a hematological response both at the time of dialysis initiation or after dialysis (for those patients who required further treatment), prolonged patients’ survival. Additionally, we investigated the role of kidney biopsy in the diagnosis of renal disease in patients with underlying monoclonal gammopathies, and we demonstrated that in approximately 30% of patients the renal damage was unrelated to the monoclonal immunoglobulin, emphasizing the importance of accurate diagnosis for the implementation of the appropriate treatment. Finally, we studied the outcome of patients with MGRS other than AL amyloidosis, who received daratumumab-based treatment and we found that it is a safe and very effective option, especially when combined with bortezomib, with 44% of patients achieving CR or VGPR, while approximately half of the patients improved their renal function. We also presented here for the first time data on the use of such regimens as initial treatment in patients with MGRS, and also data on the application of next-generation flow cytometry for monitoring the response to treatment.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Theodorakakou, Foteini
- Θεοδωρακάκου, Φωτεινή
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60964